Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2011
This article has no abstract
Epistemonikos ID: df00e2ea8339470bebe383a818fd28d7ae20a5e1
First added on: Jun 11, 2017